Receiving a diagnosis of primary immune deficiency (PID), also called primary immunodeficiency disease, can feel overwhelming. You are being told that your immune system has a structural problem that limits its ability to produce the antibodies needed to fight infections. For many patients, that news is followed almost immediately by a recommendation to start immunoglobulin replacement therapy.
This guide is for patients who are newly diagnosed and trying to understand what IVIG treatment involves, what the long-term commitment looks like, and how
home infusion therapy fits into the picture.
Pharmko has supported PID patients across 22+ states through the full arc of this therapy, from first infusion to long-term maintenance.
What Is Primary Immune Deficiency?
Primary immune deficiency is an umbrella term for a group of conditions in which a component of the immune system, most commonly the ability to produce immunoglobulins (antibodies), is absent, reduced, or dysfunctional. Unlike secondary immune deficiencies caused by medications, HIV, or cancer treatment, PIDs are intrinsic conditions resulting from genetic or developmental problems in immune cell function.
The most common forms of PID include:
- Common variable immune deficiency (CVID), the most frequently diagnosed adult PID, characterized by low IgG, IgA, and/or IgM and poor vaccine responses
- X-linked agammaglobulinemia (XLA), typically diagnosed in young males, with near-absent B cells and very low or absent immunoglobulins
- Selective IgA deficiency, the most common PID overall, though most patients are asymptomatic
- Specific antibody deficiency, normal total immunoglobulin levels but inability to produce antibodies to specific antigens (e.g., polysaccharide vaccines)
- Combined immune deficiencies, conditions affecting both B and T cell function, typically more severe
Diagnosis is made through immunoglobulin quantification, vaccine antibody titers, and in some cases lymphocyte subset analysis and genetic testing.
Why IVIG Is Prescribed for PID
In patients with PIDs characterized by low or absent IgG, the immune system cannot produce adequate antibodies to fight bacterial infections. This leads to recurrent, serious infections — particularly pneumonia, sinusitis, and ear infections, that over time can cause permanent lung damage (bronchiectasis), chronic sinusitis, and other complications.
Immunoglobulin replacement therapy, delivered as IVIG (intravenous immunoglobulin) or SCIG (subcutaneous immunoglobulin), replaces the missing antibodies with a concentrated preparation derived from pooled donated plasma. Regular infusions maintain IgG levels above the threshold needed to prevent serious infections, effectively compensating for the immune system's inability to produce its own.
IVIG is not a cure for PID, it does not fix the underlying immune defect. But it is a highly effective long-term management strategy that allows most PID patients to live full, active lives with significantly reduced infection risk.
What to Expect from Your First IVIG Infusions
For newly diagnosed patients, the first few IVIG infusions typically occur in a supervised clinical setting, a physician's infusion suite, hospital outpatient department, or infusion center, where vital signs are monitored and any early reactions can be managed. This period allows your clinical team to:
- Identify your optimal infusion rate, some patients tolerate rapid infusion well; others require slower rates to avoid headache, fatigue, or chills
- Determine your IgG response, labs are drawn to confirm your IgG levels are reaching therapeutic range (typically 500–700 mg/dL minimum, often higher)
- Establish your dosing schedule, most patients receive IVIG every 3 to 4 weeks, though some require more frequent dosing
Once you have tolerated IVIG without significant reactions and your dosing is established, transitioning to home infusion is a natural next step for most patients. Our dedicated guide on
IVIG therapy at home covers the home infusion setup process in detail.
IVIG vs SCIG: Which Is Right for You?
Immunoglobulin replacement therapy is available in two routes, intravenous and subcutaneous, and choosing between them is a decision you make with your immunologist based on your lifestyle, vein access, and personal preference.
- IVIG: monthly or every-3-weeks infusions over 2–4 hours, administered by a nurse; IgG levels fluctuate between doses (peak after infusion, trough before next dose)
- SCIG: weekly or biweekly self-injections under the skin, smaller volume per session, more stable IgG levels, no nursing visit required after training
Neither approach is clearly superior, outcomes data show both maintain infection protection effectively when IgG targets are met. Many patients on IVIG eventually transition to SCIG once they are comfortable self-administering; others prefer the monthly nursing contact that IVIG provides.
Long-Term Considerations
PID is a lifelong condition. IVIG or SCIG therapy is typically continued indefinitely, stopping treatment leads to IgG decline and return of infection susceptibility within weeks to months. Long-term considerations include:
- Annual IgG monitoring and dose adjustments as weight, clinical status, or infection frequency changes
- Infusion-related side effects management, headache, fatigue, and mild systemic reactions are common and manageable
- Coordination with your immunologist for breakthrough infections, new diagnoses (PID patients have higher rates of autoimmune complications and certain malignancies), and evolving clinical needs
Pharmko's clinical team supports PID patients throughout this long-term journey. Our nurses conduct regular home visits, our pharmacists review labs at each refill cycle, and our 24/7 support line is available when questions arise between scheduled contacts. Know
which symptoms should prompt an immediate call and save our
after-hours support number before your first home infusion.
Insurance Coverage for IVIG in PID
IVIG for PID is covered by Medicare Part B and most commercial insurance plans when the diagnosis is documented with lab evidence of low IgG and clinical history of recurrent infections.
Pharmko manages prior authorization and works with your immunologist to compile the necessary documentation.
For patients with PID who also have autoimmune complications, a common occurrence, see our guide on
home infusion for autoimmune diseases for how those additional therapies can be coordinated.
→
Contact Pharmko to start IVIG therapy:
1-877-540-2003 ·
info@pharmko.com
